The maker of a key bird flu drug said today that sales of the treatment had more than doubled as countries stocked up ahead of a possible pandemic.
Swiss firm Roche said sales of Tamiflu, which is seen as the best treatment for bird flu, soared to Sfr279 million Swiss francs (£122 million) in its third quarter.
A number of countries, including the UK, have been stockpiling the anti-viral drug, helping Roche report a 17 per cent hike in group revenues in the three months to the end of September.
Basel-based Roche employs 1,800 staff in the UK, with its UK headquarters at Welwyn Garden City in Hertfordshire and a sales and marketing base at Lewes, East Sussex.
The firm produces more than 100 million capsules of Tamiflu a year and has already expanded its production capacity several times. It said today that it would take action to further boost production.
Since 2003, around 120 people worldwide have been diagnosed with the potentially lethal H5N1 bird flu strain, leading to 60 deaths.
Experts believe it is inevitable that a pandemic will emerge and could kill more than 50,000 people in the UK alone.
In March, the Department of Health announced the purchase of 14.6 million courses of Tamiflu. Broker Merrill Lynch said the Tamiflu sales figures were ahead of its forecasts.
Worldwide, Roche employs around 65,000 staff in 150 countries.